Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D
Department of Haematology, Sheba Medical Centre, Tel Hashomer, Israel.
Br J Haematol. 1992 Dec;82(4):729-34. doi: 10.1111/j.1365-2141.1992.tb06951.x.
Surgical interventions in patients suffering from haemophilia A require infusions of large doses of factor VIII (F VIII) concentrates. These are expensive and may pose a burden on the immune system, which is already compromised in many haemophiliacs. F VIII is usually given as bolus injections, although there are reports on fixed dose continuous infusion. We have developed a continuous infusion programme with dosage adjusted according to daily calculation of the clearance of F VIII. Twenty-four haemophiliacs received a total of 205 d of continuous infusion with F VIII (168 d in hospital, 37 d home therapy). Eighteen patients underwent surgeries (11 elective, seven emergency) and six were treated for serious haemorrhages. We observed a significant, progressive decrease of the clearance of F VIII over the first 5 d from 3.2 (2.8-3.5) to 1.7 (1.3-1.9) ml/kg/h (median and interquartile range). The decrease of the clearance together with the fact that a continuous infusion requires less drug than bolus injections to keep the same minimal concentration, contributed to much lower doses of F VIII than reported in the literature or than required by historical controls, matched for the type of operation. Other advantages of our method are improved safety with stable activities of F VIII, lack of hazardous troughs below the haemostatic range, and the convenience, which permits ambulant therapy even when high doses of F VIII are required.
对甲型血友病患者进行外科手术干预需要输注大剂量的凝血因子VIII(F VIII)浓缩物。这些浓缩物价格昂贵,而且可能给免疫系统带来负担,而许多血友病患者的免疫系统已经受损。F VIII通常以大剂量注射给药,不过也有关于固定剂量持续输注的报道。我们制定了一个持续输注方案,其剂量根据F VIII清除率的每日计算结果进行调整。24名血友病患者接受了总计205天的F VIII持续输注(168天住院治疗,37天家庭治疗)。18名患者接受了手术(11例择期手术,7例急诊手术),6名患者因严重出血接受治疗。我们观察到,在最初5天内,F VIII的清除率从3.2(2.8 - 3.5)显著逐步下降至1.7(1.3 - 1.9)ml/kg/h(中位数和四分位间距)。清除率的下降,以及持续输注与大剂量注射相比,在维持相同最低浓度时所需药物更少这一事实,使得F VIII的剂量远低于文献报道或历史对照(根据手术类型匹配)所要求的剂量。我们方法的其他优点包括,F VIII活性稳定,安全性提高,不会出现低于止血范围的危险低谷,以及即便需要高剂量F VIII时也方便进行门诊治疗。